Lotus Pharmaceuticals Inc. (OTC BB: LTUS) is becoming one of China’s leaders in the marketing of prescription and over the counter medications. Lotus develops high quality, low cost generic medication and other over the counter brands. Led by their CEO Dr. Liu Zhongyi, the company expects to have continued growth of 20% per year and yearly revenues of over $140 million. For further information, visit the company website at: www.lotuseast.com.
- 18 years ago
QualityStocks
Lotus Pharmaceuticals Inc. (OTC BB: LTUS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…